Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
about
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesDeciding oral drugs after metformin in type 2 diabetes: An evidence-based approachDrug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case ReportThe regulatory role of DPP4 in atherosclerotic disease.Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort studyThe nonglycemic actions of dipeptidyl peptidase-4 inhibitorsDipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearmEffect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study.Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
P2860
Q26777177-964D3984-4DFC-4AE7-9FE6-148A99D1417FQ26851797-41FA5310-B3D9-44ED-9C7D-9C8230BC5A09Q33751504-2CC7B5CC-34FB-4662-87B1-5323E146B0A3Q33805518-55D7AD89-29D3-4D7E-BF17-1D67C5539E29Q33833732-E3C412D8-0238-47E8-B433-2324638E5B15Q34029715-635F8CC8-8D6C-4835-A7D9-84BE3DE5F74EQ35026385-898E3508-E918-4A2F-A6DC-4693C521493FQ36119669-94EA4F16-EE0B-40D0-A832-CB766096678BQ37129133-02A416B9-5AFB-4AE3-A54A-67A94964121DQ38410742-84EB816C-3057-4AA4-B19A-10C4FAB4E952Q38722045-BD746FB5-F68A-44EF-8DE7-63DD1D416D29Q38751579-E35E4543-C3B9-4D32-822F-688065DCF654Q38825446-2ADD41DD-E9D2-4E9D-BD66-3CDC2FCD6362Q41907589-5173936E-4568-4EE0-9DCC-5CAA9DD48EF6Q42175983-8C42AA39-0243-43E5-8F56-B27AFE9ED6D5Q55053753-4D278AA3-EB41-406A-B2BE-251C558A1B9B
P2860
Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Substance P increases sympathe ...... ptidyl peptidase-4 inhibition.
@en
Substance P increases sympathe ...... ptidyl peptidase-4 inhibition.
@nl
type
label
Substance P increases sympathe ...... ptidyl peptidase-4 inhibition.
@en
Substance P increases sympathe ...... ptidyl peptidase-4 inhibition.
@nl
prefLabel
Substance P increases sympathe ...... ptidyl peptidase-4 inhibition.
@en
Substance P increases sympathe ...... ptidyl peptidase-4 inhibition.
@nl
P2093
P2860
P1433
P1476
Substance P increases sympathe ...... eptidyl peptidase-4 inhibition
@en
P2093
Jessica K Devin
Mias Pretorius
Nancy J Brown
P2860
P304
P356
10.1161/HYPERTENSIONAHA.113.02767
P407
P577
2014-02-10T00:00:00Z